Exchange data showed that around 60.8 lakh shares, representing nearly 2.3% of the company’s outstanding equity, changed hands in the transaction. The identities of the buyer and seller were not immediately known.
Separately, the company said it expects to report revenue of more than ₹150 crore in the June quarter, which would mark one of the strongest quarterly performances in its history.
Buoyed by the strong start to FY27 and improving business visibility across domestic and international markets, Cupid has raised its full-year revenue guidance by at least 10%. The company now expects FY27 revenue to exceed ₹660 crore, compared with its earlier guidance of ₹600 crore.
Cupid said the upgraded outlook is supported by rising opportunities in international B2B healthcare markets, driven by demand from institutional customers, private buyers and government procurement programmes.
The company also expects to benefit from the commencement of its long-term supply agreement with the Partnership for Supply Chain Management (PFSCM), Netherlands, which it believes will strengthen its presence in global healthcare procurement.
In addition, Cupid sees significant growth potential in its lubricant portfolio amid rising adoption across institutional and consumer segments. It also expects its consumer business to benefit from the continued expansion of its personal care and wellness products across modern trade, organised retail and pharmacy networks across India.
